

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Foslevodopa-foscarbidopa for treating Parkinson's disease with motor symptoms [ID3876]

Final Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AbbVie (foslevodopa-foscarbidopa) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain and Spine Foundation • Brain Charity • Dementia Carers Count • Dementia UK • Innovations in Dementia • Neurological Alliance • Parkinson's UK • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Directors of Adult Social Services • British Association for Psychopharmacology • British Association of Neuroscience Nurses • British Geriatrics Society • British Neuropathological Society • British Neuropsychiatry Association • Institute of Neurology • Neuromodulation Society of UK and Ireland • Parkinson's Disease Nurse Specialist Association • Primary Care and Community Neurology Society • Royal College of General Practitioners 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (levodopa-carbidopa intestinal gel) • Accord Healthcare (pramipexole, ropinirole, rasagiline) • Aspire Pharma (pramipexole) • Aurobindo Pharma (pramipexole, ropinirole, rasagiline) • Bial Pharma UK (opicapone) • Boehringer Ingelheim (pramipexole)

Final stakeholder list for the single technology appraisal of foslevodopa-foscarbidopa for treating Parkinson's disease with motor symptoms

Issue date: April 2022

© National Institute for Health and Care Excellence 2022. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Herts Valleys CCG • NHS North Norfolk CCG • Welsh Government 	<ul style="list-style-type: none"> • Britannia Pharmaceuticals (apomorphine) • Brown and Burk UK (rasagiline) • Dr Reddy's Laboratories UK (rasagiline) • Ever Pharma UK (apomorphine) • Fontus Health (amantadine) • GlaxoSmithKline UK (ropinirole) • Glenmark Pharmaceuticals (pramipexole, rasagiline) • Lupin Healthcare UK (ropinirole) • Martindale Pharma (pramipexole, ropinirole) • Meda Pharmaceuticals (tolcapone) • Mylan (pramipexole, ropinirole, bromocriptine) • Orion Pharma (selegiline, entacapone) • Pfizer (cabergoline) • Profile Pharma (safinamide) • Rivopharm UK (rasagiline) • Teva Pharmaceuticals (rasagiline) • UCB Pharma (rotigotine) • Zentiva (pramipexole, rasagiline) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Neurological Research Trust • Cochrane UK • Cure Parkinson's • Genomics England • Institute for Ageing and Health • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • Research Institute for the Care of Older People • UK Parkinson's Disease Consortium <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.